ClinicalTrials.gg
CompletedNCT01810380Updated Mar 16, 2017Results posted

Brexpiprazole in Patients With Acute Schizophrenia

A Phase 3 interventional study of Placebo and Brexpiprazole in Schizophrenia, sponsored by H. Lundbeck A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-16.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
5th of 28
468 · median 155
Started
2013
with 5 others
Phase 3
16 of 28
none open now
Registered
13th of 28
by date
Lead sponsor
3 of 28
H. Lundbeck A/S

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 5th largest by enrollment, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 13th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has schizophrenia, diagnosed according to ™ and confirmed by the Mini International Neuropsychiatric Interview (MINI).
  • The patient has an acute exacerbation of psychotic symptoms and marked deterioration of usual function.
  • The patient is willing to be hospitalised from the Screening Visit through Week 6.
  • The patient will benefit from hospitalisation or continued hospitalisation for treatment of a current acute relapse of schizophrenia at study entry.
  • The patient has a history of relapse and/or exacerbation of symptoms when not receiving antipsychotic treatment, excluding the current episode.
  • The patient agrees to protocol-defined use of effective .

Exclusion criteria

Exclusion Criteria:

  • The patient has a current Axis I diagnosis (™ criteria) other than schizophrenia established as primary diagnosis.
  • The patient suffers from a current Axis II diagnosis (DSM-IV-TR™ criteria).
  • The patient suffers from mental retardation, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient, in the opinion of the investigator or according to Columbia Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.
  • The patient has tardive dyskinesia or severe akathisia at enrolment.
  • The patient has a history of neuroleptic malignant syndrome.
  • The patient has any relevant medical history or current presence of systemic disease.
  • The patient has, at the Screening Visit an abnormal or other abnormal ECG tests that are, in the investigator's opinion, clinically significant.
  • The patient has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, that has not been in remission for >5 years prior to the first dose of brexpiprazole.
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
468 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Brexpiprazole

    Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.

    Drug: Brexpiprazole

  • Other
    Quetiapine extended release

    Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.

    Drug: Quetiapine extended release

Interventions

  • DrugPlacebo

    Once daily as tablets and capsules, orally

  • 2-4 mg/day, once daily, tablets, orally

  • 400-800 mg/day, once daily, encapsulated tablets, orally

    Also known as: Seroquel XL®/XR®

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in PANSS Total Score

    The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale for assessing the symptoms of schizophrenia. For each PANSS item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score (30 items) ranged from 30 to 210 with a higher score indicating greater severity of symptoms.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Change From Baseline to Week 6 in CGI-S Score

    The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline and Week 6

  2. CGI-I Score at Week 6

    The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.

    Time frame: Week 6

  3. Change From Baseline to Week 6 in PANSS Positive Subscale Score

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Positive Subscale score is calculated from 7 items (for example: delusions, conceptual disorganization and hallucinatory behaviour). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  4. Change From Baseline to Week 6 in PANSS Negative Subscale Score

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Negative Subscale score is calculated from 7 items (for example: blunted affect, emotional withdrawal and poor rapport). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  5. Change From Baseline to Week 6 in PANSS General Psychopathology Subscale Score

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS General Psychopathology Subscale score is calculated from 16 items (for example: somatic concern, anxiety and guilt feelings). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  6. Change From Baseline to Week 6 in PANSS Excited Component Score

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Excited Component score is calculated from 5 items (for example: poor impulse control, tension and hostility). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  7. Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: negative symptoms is calculated from 7 items (for example: blunted affect, emotional withdrawal and motor retardation). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  8. Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: positive symptoms is calculated from 8 items (for example: delusions, conceptual disorganization and stereotype thinking). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  9. Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: disorganized thoughts is calculated from 7 items (for example: conceptual disorganization, difficulty in abstract thinking and mannerisms and posturing). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  10. Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: uncontrolled hostility/excitement is calculated from 4 items (for example: excitement, hostility, and uncooperativeness).Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  11. Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression

    The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: anxiety/depression is calculated from 4 items (for example: anxiety, guilt feelings, and tension). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

    Time frame: Baseline and Week 6

  12. Discontinuation Due to Lack of Efficacy During the Study

    Discontinuation due to lack of efficacy was based on the primary reason for withdrawal

    Time frame: Baseline to Week 6

  13. Response Rate at Week 6

    The response rate was defined as a reduction of ≥30% from baseline in PANSS total score OR a CGI-I score of 1 or 2

    Time frame: Baseline and Week 6

  14. Change From Baseline to Week 6 in PSP Total Score

    The Personal and Social Performance Scale (PSP) is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. The PSP scale consists of a 100-point single-item rating scale, subdivided into 10 equal intervals. Scores of 1 to 10 indicate lack of autonomy in basic functioning, whereas scores of 91 to 100 reflect excellent functioning. The total score is rated by the investigator and is based on an algorithm which takes both the ratings of the 4 primary domains of PSP, and the combination of these ratings into account. The 4 primary domains are: socially useful activities (including work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. The 4 domains are assessed on a 6-point scale, from absent to very severe. A higher score indicates a better performance.

    Time frame: Baseline and Week 6

  15. PSP Functional Remission Rate at Week 6

    The PSP functional remission rate was defined as a PSP total score ≥71

    Time frame: Week 6

  16. PSP Functional Response Rate at Week 6

    The PSP functional response rate was defined as ≥10 point improvement from Baseline on the PSP total score

    Time frame: Week 6

  17. PSP Domain D: Disturbing and Aggressive Behaviours at Week 6

    PSP domain D: disturbing and aggressive behaviours were categorised as "aggressive" (corresponding to mild, manifest, marked, severe, or very severe) or "nonaggressive" (corresponding to absent)

    Time frame: Week 6

07

Results

Posted Mar 29, 2016

Participant flow

Participant flow — Overall Study
MilestonePlaceboBrexpiprazoleQuetiapine Extended Release
Started163151154
Treated161150153
Completed108113122
Not completed553832
Withdrew: Randomised not treated211
Withdrew: Adverse event11144
Withdrew: Lack of efficacy241011
Withdrew: Protocol violation101
Withdrew: Withdrawal by subject606
Withdrew: Administrative or other reasons11139

Outcome measures

PrimaryChange From Baseline to Week 6 in PANSS Total Score

The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale for assessing the symptoms of schizophrenia. For each PANSS item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score (30 items) ranged from 30 to 210 with a higher score indicating greater severity of symptoms.

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Total Score
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Total Score-15.9 ± 1.5-20.0 ± 1.5-24.0 ± 1.5
Statistical analysis
  • Placebo vs Brexpiprazole · Mixed Models Analysis · p = 0.0560 (For all efficacy analyses the primary comparison is the difference between brexpiprazole 2 to 4 mg/day and placebo at Week 6.) · Least square mean difference: -4.1 · 95% CI -8.2 to 0.1Pooled site, visit, treatment as fixed effects, baseline score as continuous covariate, treatment-by-visit and baseline score-by-visit as interactions
  • Placebo vs Quetiapine Extended Release · Mixed Models Analysis · p = 0.0002 · Least square mean difference: -8.0 · 95% CI -12.2 to -3.9
SecondaryChange From Baseline to Week 6 in CGI-S Score

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in CGI-S Score
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in CGI-S Score-0.9 ± 0.1-1.2 ± 0.1-1.4 ± 0.1
SecondaryCGI-I Score at Week 6

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.

Time frame:
Week 6
Reported as:
Mean · units on a scale
CGI-I Score at Week 6
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
CGI-I Score at Week 63.0 ± 0.12.7 ± 0.12.5 ± 0.1
SecondaryChange From Baseline to Week 6 in PANSS Positive Subscale Score

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Positive Subscale score is calculated from 7 items (for example: delusions, conceptual disorganization and hallucinatory behaviour). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Positive Subscale Score
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Positive Subscale Score-5.4 ± 0.5-7.0 ± 0.5-8.1 ± 0.5
SecondaryChange From Baseline to Week 6 in PANSS Negative Subscale Score

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Negative Subscale score is calculated from 7 items (for example: blunted affect, emotional withdrawal and poor rapport). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Negative Subscale Score
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Negative Subscale Score-3.1 ± 0.4-3.7 ± 0.4-4.5 ± 0.4
SecondaryChange From Baseline to Week 6 in PANSS General Psychopathology Subscale Score

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS General Psychopathology Subscale score is calculated from 16 items (for example: somatic concern, anxiety and guilt feelings). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS General Psychopathology Subscale Score
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS General Psychopathology Subscale Score-8.2 ± 0.7-9.9 ± 0.7-11.6 ± 0.7
SecondaryChange From Baseline to Week 6 in PANSS Excited Component Score

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Excited Component score is calculated from 5 items (for example: poor impulse control, tension and hostility). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Excited Component Score
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Excited Component Score-2.5 ± 0.3-3.3 ± 0.3-3.9 ± 0.3
SecondaryChange From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: negative symptoms is calculated from 7 items (for example: blunted affect, emotional withdrawal and motor retardation). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms-3.6 ± 0.4-4.3 ± 0.4-4.8 ± 0.4
SecondaryChange From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: positive symptoms is calculated from 8 items (for example: delusions, conceptual disorganization and stereotype thinking). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms-5.7 ± 0.5-7.1 ± 0.5-8.4 ± 0.5
SecondaryChange From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: disorganized thoughts is calculated from 7 items (for example: conceptual disorganization, difficulty in abstract thinking and mannerisms and posturing). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts-3.2 ± 0.4-4.0 ± 0.4-4.8 ± 0.3
SecondaryChange From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: uncontrolled hostility/excitement is calculated from 4 items (for example: excitement, hostility, and uncooperativeness).Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement-1.8 ± 0.3-2.5 ± 0.3-2.8 ± 0.3
SecondaryChange From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression

The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: anxiety/depression is calculated from 4 items (for example: anxiety, guilt feelings, and tension). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression-2.9 ± 0.2-3.2 ± 0.2-3.6 ± 0.2
SecondaryDiscontinuation Due to Lack of Efficacy During the Study

Discontinuation due to lack of efficacy was based on the primary reason for withdrawal

Time frame:
Baseline to Week 6
Reported as:
Number · percentage of patients
Discontinuation Due to Lack of Efficacy During the Study
percentage of patientsPlaceboBrexpiprazoleQuetiapine Extended Release
Discontinuation Due to Lack of Efficacy During the Study14.916.677.19
SecondaryResponse Rate at Week 6

The response rate was defined as a reduction of ≥30% from baseline in PANSS total score OR a CGI-I score of 1 or 2

Time frame:
Baseline and Week 6
Reported as:
Number · percentage of responders
Response Rate at Week 6
percentage of respondersPlaceboBrexpiprazoleQuetiapine Extended Release
Response Rate at Week 632.148.762.7
SecondaryChange From Baseline to Week 6 in PSP Total Score

The Personal and Social Performance Scale (PSP) is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. The PSP scale consists of a 100-point single-item rating scale, subdivided into 10 equal intervals. Scores of 1 to 10 indicate lack of autonomy in basic functioning, whereas scores of 91 to 100 reflect excellent functioning. The total score is rated by the investigator and is based on an algorithm which takes both the ratings of the 4 primary domains of PSP, and the combination of these ratings into account. The 4 primary domains are: socially useful activities (including work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. The 4 domains are assessed on a 6-point scale, from absent to very severe. A higher score indicates a better performance.

Time frame:
Baseline and Week 6
Reported as:
Mean · units on a scale
Change From Baseline to Week 6 in PSP Total Score
units on a scalePlaceboBrexpiprazoleQuetiapine Extended Release
Change From Baseline to Week 6 in PSP Total Score9.4 ± 1.013.0 ± 1.015.3 ± 1.0
SecondaryPSP Functional Remission Rate at Week 6

The PSP functional remission rate was defined as a PSP total score ≥71

Time frame:
Week 6
Reported as:
Number · percentage of remitters
PSP Functional Remission Rate at Week 6
percentage of remittersPlaceboBrexpiprazoleQuetiapine Extended Release
PSP Functional Remission Rate at Week 65.79.614.4
SecondaryPSP Functional Response Rate at Week 6

The PSP functional response rate was defined as ≥10 point improvement from Baseline on the PSP total score

Time frame:
Week 6
Reported as:
Number · percentage of responders
PSP Functional Response Rate at Week 6
percentage of respondersPlaceboBrexpiprazoleQuetiapine Extended Release
PSP Functional Response Rate at Week 636.353.464.4
SecondaryPSP Domain D: Disturbing and Aggressive Behaviours at Week 6

PSP domain D: disturbing and aggressive behaviours were categorised as "aggressive" (corresponding to mild, manifest, marked, severe, or very severe) or "nonaggressive" (corresponding to absent)

Time frame:
Week 6
Reported as:
Number · percentage of aggressive patients
PSP Domain D: Disturbing and Aggressive Behaviours at Week 6
percentage of aggressive patientsPlaceboBrexpiprazoleQuetiapine Extended Release
PSP Domain D: Disturbing and Aggressive Behaviours at Week 630.427.222.2

Adverse events

Collected over Baseline to end of treatment (Week 6). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/161 (3.7%)44/161 (27.3%)
Brexpiprazole—7/150 (4.7%)48/150 (32%)
Quetiapine—2/153 (1.3%)73/153 (47.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboBrexpiprazoleQuetiapine
SchizophreniaPsychiatric disorders4/1613/1501/153
Type 2 diabetes mellitusMetabolism and nutrition disorders0/1611/1500/153
Grand mal convulsionNervous system disorders0/1611/1500/153
Suicide attemptPsychiatric disorders0/1611/1500/153
AngioedemaSkin and subcutaneous tissue disorders0/1611/1500/153
Psychotic disorderPsychiatric disorders1/1610/1501/153
AnxietyPsychiatric disorders1/1610/1500/153
Schizophrenia, paranoid typePsychiatric disorders1/1610/1500/153
Most frequent other events
Most frequent other events
EventPlaceboBrexpiprazoleQuetiapine
SomnolenceNervous system disorders8/1617/15034/153
Weight increasedInvestigations6/1618/15020/153
DizzinessNervous system disorders1/1614/15018/153
InsomniaPsychiatric disorders10/16113/1504/153
Dry mouthGastrointestinal disorders2/1612/15013/153
HeadacheNervous system disorders11/1618/1509/153
SchizophreniaPsychiatric disorders11/1616/1504/153
AkathisiaNervous system disorders4/1619/1506/153
SedationNervous system disorders5/1614/1508/153

Baseline characteristics

all-patients-treated set (APTS)

Age, Continuous
Age, Continuous(years)PlaceboBrexpiprazoleQuetiapine Extended ReleaseTotal
Mean40.85 ± 10.5639.68 ± 10.8741.12 ± 10.9140.56 ± 10.77
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBrexpiprazoleQuetiapine Extended ReleaseTotal
Female706664200
Male918489264
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBrexpiprazoleQuetiapine Extended ReleaseTotal
American Indian or Alaska Native0101
Asian2103
Native Hawaiian or Other Pacific Islander1012
Black or African American353338106
White123113113349
More than one race0000
Unknown or Not Reported0213
Region of Enrollment
Region of Enrollment(participants)PlaceboBrexpiprazoleQuetiapine Extended ReleaseTotal
United States505256158
Estonia43411
France1012
Poland55515
Romania14131138
Serbia13111135
Slovakia1113
Ukraine30282987
Russian Federation433735115
Time since schizophrenia diagnosis (years)
Time since schizophrenia diagnosis (years)(years)PlaceboBrexpiprazoleQuetiapine Extended ReleaseTotal
Mean14.15 ± 9.3512.88 ± 9.4313.78 ± 9.4913.62 ± 9.42
Time since first antipsychotic treatment (years)
Time since first antipsychotic treatment (years)(years)PlaceboBrexpiprazoleQuetiapine Extended ReleaseTotal
Mean14.48 ± 8.9813.43 ± 9.1914.31 ± 9.3414.08 ± 9.16
PANSS total score
PANSS total score(units on a scale)PlaceboBrexpiprazoleQuetiapine Extended ReleaseTotal
Mean98.38 ± 10.3097.82 ± 10.2598.82 ± 10.8398.34 ± 10.45
CGI-S Score
CGI-S Score(units on a scale)PlaceboBrexpiprazoleQuetiapine Extended ReleaseTotal
Mean4.94 ± 0.574.96 ± 0.594.98 ± 0.574.96 ± 0.58
08

Study locations

1 site
  • US009
    Escondido, California 92025, United States
09

References and documents

Publications

  • Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793. PubMed 35235720 ↗
  • Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan. PubMed 34901863 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2013
First posted
Mar 13, 2013
Start
Mar 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Mar 29, 2016
Last update
Mar 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01810380
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 13, 2013
Start date
Mar 2013
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Mar 29, 2016
Last update
Mar 16, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion